/Companies

Centese

Omaha, US · Delaware corporation · 4 known investors

Find your way into Centese

Sign up to see every warm intro you have to Centese

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Centese team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Centese develops Thoraguard, a digital surgical drainage system for cardiothoracic surgery that automates chest tube clog clearance and measures air leak rate and drainage volume, alerting care teams to disruptions. The system is aimed at clinicians and ICU/critical care teams to support post-operative patient monitoring and recovery.

Founders & leadership

ELEvan Luxon
Evan LuxonCo-Founder
RPRandy Preston
Randy PrestonCEORandy Preston has spent two decades in medical device development, with cross-functional experience spanning product development, clinical work, program management, and market development. He is CEO of Centese, which develops Thoraguard, a digital surgical drainage system for cardiothoracic surgery.
AC
Alan CheslerNamed on SEC filing

Board

RC
Radu CautisBoard directorGeneral Partner at Medical Technology Venture Partners
DB
Daniel BurnettBoard director
DG
Deepak GangaharBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$15.9M disclosed across 3 rounds · 2023–2026

▶$250KraisedMay 2026 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Randy PrestonExecutive Officer, Director
  • Daniel BurnettDirector
  • Deepak GangaharDirector
  • Radu CautisDirector
Offering amount
$5M
Amount sold
$250K
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$525KraisedMay 2025 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Evan LuxonExecutive Officer, Director
  • Radu CautisDirector
  • Daniel BurnettDirector
  • Deepak GangaharDirector
Offering amount
$6.5M
Amount sold
$525K
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.1MraisedNov 2023 · 50 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan CheslerDirector
  • Dan BurnettDirector
  • Deepak GangaharDirector
  • Radu CautisDirector
  • Evan LuxonExecutive Officer, Director
Offering amount
$23.1M
Amount sold
$15.1M
Minimum investment
$1
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as Centese.

In the news

Frequently asked questions

What does Centese do?
Centese develops Thoraguard, a digital surgical drainage system for cardiothoracic surgery that automates chest tube clog clearance and measures air leak rate and drainage volume, alerting care teams to disruptions. The system is aimed at clinicians and ICU/critical care teams to support post-operative patient monitoring and recovery.
Who founded Centese?
Centese was founded by Evan Luxon.
Who are Centese's investors?
Centese's investors include Invest Nebraska, New York Angels, Scientific Health Development, Medical Technology Venture Partners.
How much funding has Centese raised?
Centese has disclosed $15.9M raised across 3 rounds.
Where is Centese headquartered?
Centese is headquartered in Omaha, US.